Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 35,388 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Renal Cell Carcinoma
Interventions: TRC105 and Axitinib, Axitinib; Drug
Lead sponsor: Tracon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 28
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 23 more

Conditions: Lymphoma, Marginal Zone Lymphoma, MZL
Interventions: Venetoclax, Rituximab; Drug
Lead sponsor: Gottfried von Keudell, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Skin Aging, Skin Wrinkling
Interventions: PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, saline solution (placebo); Drug
Lead sponsor: Kalpna Kay Durairaj, MD, FACS; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Colitis, Ulcerative
Interventions: PF-06480605; Drug
Lead sponsor: Telavant, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 12
States / cities: Aventura, Florida • North Miami Beach, Florida • Pembroke Pines, Florida + 5 more

Conditions: SCLC
Interventions: Topotecan - usual, Topotecan - study; Drug
Lead sponsor: Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair; Industry
Eligibility: 24 Years to 64 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Prostate Cancer
Interventions: pTVG-HP, rhGM-CSF; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Madison, Wisconsin

Conditions: Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
Interventions: MEDI3617, Bevacizumab, Paclitaxel, Carboplatin; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 10
States / cities: Los Angeles, California • Stanford, California • Lafayette, Indiana + 7 more

Conditions: Spasmodic Dysphonia, Voice Tremor
Interventions: Sodium Oxybate; Drug
Lead sponsor: Kristina Simonyan; Other
Eligibility: 21 Years to 80 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Interventions: NVX-CoV2705 Vaccine; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Phoenix, Arizona • Austin, Texas

Conditions: Sarcoma
Interventions: Surgical Resection, Intensity Modulated Radiation Therapy (IMRT); Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: X-Linked Chronic Granulomatous Disease
Interventions: EN-374; Genetic
Lead sponsor: Ensoma; Industry
Eligibility: 3 Months and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • St. Petersburg, Florida + 5 more

Conditions: Overweight, Obesity
Interventions: UBT251, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Cypress, California • Overland Park, Kansas

Conditions: Diabetes Mellitus, Type 1
Interventions: text message to parent only, text message to parent and adolescent; Other
Lead sponsor: University of Louisville; Other
Eligibility: 8 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Non Small Cell Lung Cancer NSCLC
Interventions: Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 16
States / cities: Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 13 more

Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: IMNN-001, Carboplatin, Paclitaxel; Biological · Drug
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • Mobile, Alabama • Newport Beach, California + 17 more

Conditions: College Student Drinking
Interventions: e-checkup to go, Delayed feedback booster; Behavioral
Lead sponsor: Abby Braitman; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Inflammatory Disease
Interventions: Lanraplenib.; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida

Conditions: Lung Cancer
Interventions: cisplatin, etoposide, tirapazamine, radiation therapy; Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 87
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more

Conditions: Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Neratinib Maleate, Trastuzumab Deruxtecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 18
States / cities: Duarte, California • Irvine, California • Lancaster, California + 13 more

Conditions: Bacterial Infections
Interventions: Dalbavancin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: San Diego, California • Louisville, Kentucky • Cleveland, Ohio

Conditions: Oral Bacteria, Halitosis
Interventions: Streptococcus salivarius DB-B5 - 2 billion CFU/day, Streptococcus salivarius DB-B5 - 10 billion CFU/day, Placebo; Dietary Supplement · Other
Lead sponsor: Dose Biosystems Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI), Overactive Bladder (OAB)
Interventions: Axonics External Trial System (ETS); Device
Lead sponsor: Axonics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 3
States / cities: Birmingham, Alabama • Macon, Georgia • West Columbia, South Carolina

Conditions: Hepatitis B Virus
Interventions: Non-Framed-Offered, Non-Framed-Recommended, Gain-Framed-Offered, Gain-Framed-Recommended, Loss-Framed-Offered, Loss-Framed-Recommended; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 1,747 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 2
States / cities: Chicago, Illinois • Indianapolis, Indiana

Conditions: Recurrent Respiratory Papillomatosis
Interventions: Avastin® (bevacizumab), Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.

Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms

Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor

A Strain Change Study for SARS-CoV-2 rS Vaccines

A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma

Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

Personalized Feedback After Alcohol Health Education for Members of Greek Life (GREEK Study)

Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function

S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

Effect of a Probiotic Water on Oral Health in Adults

Aquarius Pilot Study to Evaluate the New Axonics Trial System

Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics

Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)